Business & Economy · 5 views
The Heart Drug Pelacarsen Fails, Shocking Novartis and Cardiologists
Doctors were hopeful the drug, which was being tested in a large clinical trial by Novartis, was going to be a powerful new tool to fight heart disease.
AI Summary
Novartis’s heart‑disease drug pelacarsen, which was being evaluated in a large clinical trial, has failed to meet its objectives, surprising both the company and cardiologists. Doctors had previously been hopeful that the experimental therapy would become a powerful new tool against heart disease.
AI summaries can be wrong sometimes—always verify important details using the source article.
How AI & Automation are usedMore from Business & Economy
Continue reading recent Business & Economy coverage
- OpenAI quietly boosts some of Astra’s evaluation metrics, and continues to change others post-launchContinue reading
- 4 things investigators learned about the dysfunction at Trump's Labor DepartmentContinue reading
- Bloom Energy was just named to the S&P 500. These other stocks are joining the index as well.Continue reading
- Bitcoin is trading more like an ‘amplified version of gold’ again, but the four-year cycle theory threatens further declinesContinue reading
Support HappeningNow
Independent AI-powered news analysis is reader-supported. Your contribution helps cover infrastructure, summaries, and continued platform development.
Support HappeningNow